Drugs / Flovent HFA
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FLOVENT HFA | — | 2006-02-28 | fda.gov ↗ |
| Approved | US (FDA) | FLOVENT HFA | — | 2004-05-14 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02266927 Comparator | Sep 2014 → Mar 2015 | asthma | Optinose US Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flovent HFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02266927 ↗ |
| Route | Inhaled | “Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg” NCT02266927 ↗ |